Page last updated: 2024-11-07

ilomastat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CS 610: matrix metalloproteinase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID132519
CHEMBL ID19611
CHEBI ID137236
SCHEMBL ID35303
MeSH IDM0305265

Synonyms (89)

Synonym
CBIOL_001883
unii-i0403ml141
i0403ml141 ,
ilomastat [usan:inn]
galardin mpi
cs-610
galardin
ilomastat
gm-6001
ilomastat (usan/inn)
D03793
142880-36-2
BIO2_000850
BIO1_001147
BIO2_000370
BIO1_000658
BIO1_000169
SMP2_000212
3-(n-hydroxycarboxamido)-2-isobutylpropanoyl-trp-methylamide
gm6001 ,
DB02255
BCBCMAP01_000057
gm 6001
NCGC00163450-01
KBIO2_005555
KBIO3_000798
KBIOSS_000419
KBIO2_000419
KBIOGR_000419
KBIO2_002987
KBIO3_000797
BSPBIO_001079
nsc-727632
nsc727632
IDI1_002125
NCGC00163450-03
butanediamide, n4-hydroxy-n1-(1-(1h-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (s-(r*,s*))-
(s-(r*,s*))-n(sup 4)-hydroxy-n(sup 1)-(1h-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylopropyl)butanediamide
(r)-n(sup 1)-hydroxy-n-((s)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide
butanediamide, n4-hydroxy-n1-((1s)-1-(1h-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (2r)-
cs 610
ilomastat [usan]
NCGC00163450-02
(2r)-n(4)-hydroxy-n(1)-[(2s)-3-(1h-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
CHEBI:137236
HMS1990E21
CHEMBL19611 ,
HMS1792E21
HMS1362E21
(r)-n*4*-hydroxy-n*1*-[(s)-2-(1h-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide
(r)-n1-((s)-3-(1h-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl)-n4-hydroxy-2-isobutylsuccinamide
(r)-n*4*-hydroxy-n*1*-[2-(1h-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide
bdbm50062351
(2r)-n'-hydroxy-n-[(2s)-3-(1h-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
NCGC00163450-04
dtxsid0046353 ,
tox21_112055
cas-142880-36-2
dtxcid8026353
ilomastat [inci]
ilomastat [inn]
S7157
AKOS016355429
BRD-K51662849-001-02-1
gtpl7409
(2r)-n'-hydroxy-n-[(2s)-3-(1h-indol-3-yl)-1-methylamino-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
CCG-207857
HY-15768
CS-1701
SCHEMBL35303
ilomastat (gm6001, galardin)
(r)-n4-hydroxy-n1-[(s)-2-(1h-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide
illomastat
(2r)-n4-hydroxy-n1-[(1s)-1-(1h-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)butanediamide
HMS3403E21
mfcd03453614
4PKW
gm6001;galardin;ilomastat
EX-A765
bdbm234334
(2r)-2-[2-(hydroxyamino)-2-oxo-ethyl]-n-[(1s)-1-(1h-indol-3-ylmethyl)-2-(methylamino)-2-oxo-ethyl]-4-methyl-pentanamide
J-007712
SW218170-2
(2r)-n~4~-hydroxy-n~1~-[(1s)-1-(1h-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)butanediamide
gm 6001 - cas 142880-36-2
NITYDPDXAAFEIT-DYVFJYSZSA-N
(r)-n1-((s)-3-(1h-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl)-n4-hydroxy-2-isobutyl succinamide
AS-56152
ilomastat; gm-6001

Research Excerpts

Overview

Ilomastat is a matrix metalloproteinase inhibitor. It has shown the potential to inhibit scarring (fibrosis) by mediating healing after injury or surgery.

ExcerptReferenceRelevance
"Ilomastat is a matrix metalloproteinase inhibitor (MMPi) that has shown the potential to inhibit scarring (fibrosis) by mediating healing after injury or surgery. "( LC-MS analysis to determine the biodistribution of a polymer coated ilomastat ocular implant.
Brocchini, S; Fadda, H; Karu, K; Khaw, PT; Lockwood, A; Madaan, S; Mohamed-Ahmed, AHA, 2018
)
2.16

Effects

ExcerptReferenceRelevance
"Ilomastat-CD has the potential to be formulated as an eye drop for use as an antifibrotic, which may have implications for the prevention of scarring in many settings, for example glaucoma filtration surgery."( An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring.
Bailly, M; Brocchini, S; Khaw, PT; Li, H; Lockwood, A; Mohamed-Ahmed, AHA, 2017
)
2.52

Treatment

Ilomastat pretreatment also increased the fraction of BM hematopoietic progenitor cells (HPCs) at day 30 after irradiation.

ExcerptReferenceRelevance
"Ilomastat pretreatment also increased the fraction of BM hematopoietic progenitor cells (HPCs) and hematopoietic stem cells (HSCs) at day 30 after irradiation, and protected the spleen of mouse from irradiation."( Ilomastat contributes to the survival of mouse after irradiation via promoting the recovery of hematopoietic system.
Hu, B; Li, X; Quan, D; Zhang, F; Zhao, B, 2021
)
2.79
"Ilomastat treatment increased the survival of mice after TBI."( MMP Inhibitor Ilomastat Improves Survival of Mice Exposed to γ-Irradiation.
Hu, BR; Huang, CQ; Li, Q; Li, XM; Pan, D; Tan, Y; Xu, MC; Zhao, BQ, 2018
)
1.56

Toxicity

ExcerptReferenceRelevance
" However, clinically tested MMP inhibitors have been associated with a painful, joint-stiffening musculoskeletal side effect that may be due to their lack of selectivity."( Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
Banotai, CA; Baragi, V; Bornemeier, DA; Datta, K; Dyer, RD; Guzman, R; Han, HK; Johnson, AR; Lesch, C; Man, CF; McConnell, P; Mueller, WT; Ortwine, DF; Pavlovsky, AG; Prior, F; Roark, WH; Wilson, M; Yan, C, 2007
)
0.34
" A single subconjunctival injection of MMP inhibitor during the experimental trabeculectomy showed a less toxic affect in the rabbit cornea, conjunctiva, and ciliary body compared to MMC."( Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery.
Han, JR; Han, KE; Suh, W, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A dose-response significant inhibition of the capillary-like formation was detected when increasing concentrations of tamoxifen, ilomastat, or echistatin were added for 1 week to the culture medium of the ERCT."( In vitro evaluation of the angiostatic potential of drugs using an endothelialized tissue-engineered connective tissue.
Auger, FA; Berthod, F; Germain, L; Tremblay, PL, 2005
)
0.53
"We are developing tablet dosage forms for implantation directly into the subconjunctival space of the eye."( Characterisation of ilomastat for prolonged ocular drug release.
Brocchini, S; Fadda, HM; Gaisford, S; Khalili, A; Khaw, PT; Lockwood, A; Parkinson, G; Ru, Q; Sheridan, R, 2012
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
EC 3.4.24.24 (gelatinase A) inhibitorAn EC 3.4.24.* (metalloendopeptidase) inhibitor that interferes with the action of gelatinase A (EC 3.4.24.24).
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
L-tryptophan derivativeA proteinogenic amino acid derivative resulting from reaction of L-tryptophan at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tryptophan by a heteroatom.
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency25.11890.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency28.39740.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency23.71010.000221.22318,912.5098AID743042; AID743054
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.93030.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.08160.000229.305416,493.5996AID743075; AID743078
glucocerebrosidaseHomo sapiens (human)Potency19.95260.01268.156944.6684AID2101
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.21170.005612.367736.1254AID624044
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.47310.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency0.47310.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Disintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)IC50 (µMol)0.13560.00811.485210.0000AID241679; AID448179
Disintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)IC50 (µMol)0.00590.00590.00590.0059AID242091
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)0.00050.00051.41288.2000AID1294562
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)0.00050.00050.57393.4000AID1294562
A disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)IC50 (µMol)0.48000.10003.526710.0000AID736089
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)0.00250.00020.850210.0000AID108731; AID108737; AID109082; AID1863874; AID1912266; AID259456; AID299878; AID359842; AID409923; AID628300; AID736086
Interstitial collagenaseHomo sapiens (human)Ki0.00040.00030.49487.0000AID1863874
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)0.00310.00001.284810.0000AID107146; AID107164; AID107338; AID109580; AID1294561; AID1683070; AID1863875; AID1912253; AID259457; AID299879; AID359843; AID409924; AID736085
72 kDa type IV collagenaseHomo sapiens (human)Ki0.00040.00000.34663.0000AID107180; AID107324; AID1863875
Stromelysin-1Homo sapiens (human)IC50 (µMol)0.01040.00001.148410.0000AID107358; AID107503; AID1683069; AID1863876; AID1912267; AID299880; AID359844; AID409928; AID628299
Stromelysin-1Homo sapiens (human)Ki0.02650.00030.54258.0000AID107521; AID1863876
MatrilysinHomo sapiens (human)IC50 (µMol)0.01910.00142.085910.0000AID1912268; AID359845
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)0.00340.00000.705310.0000AID108007; AID108308; AID1294562; AID1683068; AID1802980; AID1863879; AID1912270; AID259459; AID299881; AID359847; AID409925; AID628298
Matrix metalloproteinase-9Homo sapiens (human)Ki0.00040.00020.12810.8000AID108183; AID1863879
Neutrophil collagenaseHomo sapiens (human)IC50 (µMol)0.00540.00000.927210.0000AID1912269; AID359846
Neutrophil collagenaseHomo sapiens (human)Ki0.00020.00020.17972.1000AID107987; AID1863878
Macrophage metalloelastaseHomo sapiens (human)IC50 (µMol)0.00570.00022.721710.0000AID109243; AID1350382; AID1699663; AID1912254; AID259460; AID359849; AID408845
Collagenase 3Homo sapiens (human)IC50 (µMol)0.00360.00000.767510.0000AID1912255; AID359841; AID736084
Matrix metalloproteinase-14Homo sapiens (human)IC50 (µMol)0.01020.00030.718210.0000AID109567; AID1863882; AID1912271; AID220527; AID259461; AID299882; AID359848; AID409927; AID628296; AID736083
Matrix metalloproteinase-15Homo sapiens (human)IC50 (µMol)0.00600.00603.337310.0000AID109571; AID259462
Matrix metalloproteinase-16Homo sapiens (human)IC50 (µMol)0.00800.00802.193410.0000AID109575; AID259463
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)IC50 (µMol)0.11250.00021.014010.0000AID1802979; AID241883; AID448180
Disintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)IC50 (µMol)0.02860.00102.528410.0000AID241656; AID448178
Matrix metalloproteinase-26Homo sapiens (human)IC50 (µMol)0.01700.01703.344710.0000AID107348; AID259464
Matrix metalloproteinase-17Homo sapiens (human)IC50 (µMol)0.00340.00340.00340.0034AID359850
A disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)IC50 (µMol)0.50000.50004.475010.0000AID736087
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (218)

Processvia Protein(s)Taxonomy
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
negative regulation of gene expressionDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
in utero embryonic developmentDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein phosphorylationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
negative regulation of cell adhesionDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
integrin-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
cell-cell signalingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
regulation of Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
extracellular matrix disassemblyDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
adherens junction organizationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
response to tumor necrosis factorDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
epidermal growth factor receptor ligand maturationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
monocyte activationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
pore complex assemblyDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
constitutive protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
cochlea developmentDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
postsynapse organizationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
regulation of postsynapse organizationDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein catabolic process at postsynapseDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
regulation of vasculature developmentDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
myoblast fusionDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
positive regulation of angiogenesisDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
skeletal system developmentA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
proteolysisA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular matrix disassemblyA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular matrix organizationA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
membrane protein ectodomain proteolysisMatrilysinHomo sapiens (human)
membrane protein intracellular domain proteolysisMatrilysinHomo sapiens (human)
antibacterial peptide secretionMatrilysinHomo sapiens (human)
antibacterial peptide biosynthetic processMatrilysinHomo sapiens (human)
proteolysisMatrilysinHomo sapiens (human)
response to xenobiotic stimulusMatrilysinHomo sapiens (human)
extracellular matrix disassemblyMatrilysinHomo sapiens (human)
positive regulation of cell migrationMatrilysinHomo sapiens (human)
collagen catabolic processMatrilysinHomo sapiens (human)
regulation of cell population proliferationMatrilysinHomo sapiens (human)
defense response to Gram-negative bacteriumMatrilysinHomo sapiens (human)
defense response to Gram-positive bacteriumMatrilysinHomo sapiens (human)
extracellular matrix organizationMatrilysinHomo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of microglial cell activationNeutrophil collagenaseHomo sapiens (human)
proteolysisNeutrophil collagenaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil collagenaseHomo sapiens (human)
collagen catabolic processNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor productionNeutrophil collagenaseHomo sapiens (human)
endodermal cell differentiationNeutrophil collagenaseHomo sapiens (human)
cellular response to lipopolysaccharideNeutrophil collagenaseHomo sapiens (human)
positive regulation of neuroinflammatory responseNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayNeutrophil collagenaseHomo sapiens (human)
extracellular matrix organizationNeutrophil collagenaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIMacrophage metalloelastaseHomo sapiens (human)
proteolysisMacrophage metalloelastaseHomo sapiens (human)
protein import into nucleusMacrophage metalloelastaseHomo sapiens (human)
extracellular matrix disassemblyMacrophage metalloelastaseHomo sapiens (human)
collagen catabolic processMacrophage metalloelastaseHomo sapiens (human)
positive regulation of interferon-alpha productionMacrophage metalloelastaseHomo sapiens (human)
wound healing, spreading of epidermal cellsMacrophage metalloelastaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIMacrophage metalloelastaseHomo sapiens (human)
lung alveolus developmentMacrophage metalloelastaseHomo sapiens (human)
regulation of defense response to virus by hostMacrophage metalloelastaseHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in wound healingMacrophage metalloelastaseHomo sapiens (human)
elastin catabolic processMacrophage metalloelastaseHomo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayMacrophage metalloelastaseHomo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwayMacrophage metalloelastaseHomo sapiens (human)
bronchiole developmentMacrophage metalloelastaseHomo sapiens (human)
cellular response to virusMacrophage metalloelastaseHomo sapiens (human)
response to amyloid-betaMacrophage metalloelastaseHomo sapiens (human)
negative regulation of endothelial cell-matrix adhesion via fibronectinMacrophage metalloelastaseHomo sapiens (human)
extracellular matrix organizationMacrophage metalloelastaseHomo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
angiogenesisMatrix metalloproteinase-14Homo sapiens (human)
ovarian follicle developmentMatrix metalloproteinase-14Homo sapiens (human)
response to hypoxiaMatrix metalloproteinase-14Homo sapiens (human)
endothelial cell proliferationMatrix metalloproteinase-14Homo sapiens (human)
endochondral ossificationMatrix metalloproteinase-14Homo sapiens (human)
proteolysisMatrix metalloproteinase-14Homo sapiens (human)
response to oxidative stressMatrix metalloproteinase-14Homo sapiens (human)
male gonad developmentMatrix metalloproteinase-14Homo sapiens (human)
response to mechanical stimulusMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of myotube differentiationMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of protein processingMatrix metalloproteinase-14Homo sapiens (human)
response to organic cyclic compoundMatrix metalloproteinase-14Homo sapiens (human)
protein processingMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-14Homo sapiens (human)
protein catabolic processMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell growthMatrix metalloproteinase-14Homo sapiens (human)
lung developmentMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell migrationMatrix metalloproteinase-14Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-14Homo sapiens (human)
zymogen activationMatrix metalloproteinase-14Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
chondrocyte proliferationMatrix metalloproteinase-14Homo sapiens (human)
astrocyte cell migrationMatrix metalloproteinase-14Homo sapiens (human)
response to estrogenMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of B cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of Notch signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
embryonic cranial skeleton morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
branching morphogenesis of an epithelial tubeMatrix metalloproteinase-14Homo sapiens (human)
tissue remodelingMatrix metalloproteinase-14Homo sapiens (human)
cell motilityMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of focal adhesion assemblyMatrix metalloproteinase-14Homo sapiens (human)
head developmentMatrix metalloproteinase-14Homo sapiens (human)
craniofacial suture morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of GDF15-GFRAL signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
regulation of protein localization to plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of macrophage migrationMatrix metalloproteinase-14Homo sapiens (human)
response to odorantMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-14Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-14Homo sapiens (human)
proteolysisMatrix metalloproteinase-15Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-15Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-15Homo sapiens (human)
response to estradiolMatrix metalloproteinase-15Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-15Homo sapiens (human)
protein modification processMatrix metalloproteinase-15Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-15Homo sapiens (human)
endochondral ossificationMatrix metalloproteinase-16Homo sapiens (human)
proteolysisMatrix metalloproteinase-16Homo sapiens (human)
protein processingMatrix metalloproteinase-16Homo sapiens (human)
chondrocyte proliferationMatrix metalloproteinase-16Homo sapiens (human)
embryonic cranial skeleton morphogenesisMatrix metalloproteinase-16Homo sapiens (human)
craniofacial suture morphogenesisMatrix metalloproteinase-16Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-16Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-16Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-16Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of MAP kinase activityDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
membrane protein intracellular domain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell-matrix adhesionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
integrin-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to manganese ionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell migrationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
keratinocyte differentiationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell-cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of macrophage fusionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to tumor necrosis factorDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to laminar fluid shear stressDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
monocyte activationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to hydrogen peroxideDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of protein secretionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to glucocorticoidDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of keratinocyte migrationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to calcium ionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cellular response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to antineoplastic agentDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
proteolysisMatrix metalloproteinase-26Homo sapiens (human)
negative regulation of inflammatory responseMatrix metalloproteinase-26Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-26Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-26Homo sapiens (human)
kidney developmentMatrix metalloproteinase-17Homo sapiens (human)
proteolysisMatrix metalloproteinase-17Homo sapiens (human)
drinking behaviorMatrix metalloproteinase-17Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-17Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-17Homo sapiens (human)
aortic valve morphogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
pulmonary valve morphogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
endocardial cushion morphogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
proteolysisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
myoblast fusionA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrix disassemblyA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
defense response to bacteriumA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
negative regulation of cold-induced thermogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrix organizationA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
signaling receptor bindingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein kinase bindingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein homodimerization activityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
molecular adaptor activityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
metallodipeptidase activityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
protease bindingA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
metalloendopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
protein bindingA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
peptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
metallopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
zinc ion bindingA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
endopeptidase activityMatrilysinHomo sapiens (human)
metalloendopeptidase activityMatrilysinHomo sapiens (human)
serine-type endopeptidase activityMatrilysinHomo sapiens (human)
protein bindingMatrilysinHomo sapiens (human)
metallopeptidase activityMatrilysinHomo sapiens (human)
zinc ion bindingMatrilysinHomo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
metalloendopeptidase activityNeutrophil collagenaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
peptidase activityNeutrophil collagenaseHomo sapiens (human)
zinc ion bindingNeutrophil collagenaseHomo sapiens (human)
tumor necrosis factor bindingNeutrophil collagenaseHomo sapiens (human)
core promoter sequence-specific DNA bindingMacrophage metalloelastaseHomo sapiens (human)
endopeptidase activityMacrophage metalloelastaseHomo sapiens (human)
metalloendopeptidase activityMacrophage metalloelastaseHomo sapiens (human)
serine-type endopeptidase activityMacrophage metalloelastaseHomo sapiens (human)
calcium ion bindingMacrophage metalloelastaseHomo sapiens (human)
collagen bindingMacrophage metalloelastaseHomo sapiens (human)
zinc ion bindingMacrophage metalloelastaseHomo sapiens (human)
sequence-specific DNA bindingMacrophage metalloelastaseHomo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
integrin bindingMatrix metalloproteinase-14Homo sapiens (human)
protein bindingMatrix metalloproteinase-14Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-14Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-15Homo sapiens (human)
protein bindingMatrix metalloproteinase-15Homo sapiens (human)
enzyme activator activityMatrix metalloproteinase-15Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-15Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-15Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-16Homo sapiens (human)
enzyme activator activityMatrix metalloproteinase-16Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-16Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-16Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
protein kinase C bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
collagen bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
laminin bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-26Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-26Homo sapiens (human)
enzyme activator activityMatrix metalloproteinase-17Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-17Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-17Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-17Homo sapiens (human)
endopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
metalloendopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
integrin bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
protein bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
heparin bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
peptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
metallopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
zinc ion bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
identical protein bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrix bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (57)

Processvia Protein(s)Taxonomy
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
nucleusDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
Golgi apparatusDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
Golgi-associated vesicleDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
adherens junctionDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
postsynaptic densityDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
clathrin-coated vesicleDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
axonDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
dendriteDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
specific granule membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
intracellular membrane-bounded organelleDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
extracellular exosomeDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
tertiary granule membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
perinuclear endoplasmic reticulumDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
synaptic membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
tetraspanin-enriched microdomainDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
glutamatergic synapseDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
pore complexDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
synaptic membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 10Homo sapiens (human)
extracellular regionDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
nucleoplasmDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 12Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
extracellular regionA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular spaceA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
nuclear speckA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
collagen-containing extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular regionMatrilysinHomo sapiens (human)
extracellular matrixMatrilysinHomo sapiens (human)
extracellular exosomeMatrilysinHomo sapiens (human)
extracellular spaceMatrilysinHomo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
extracellular regionNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
specific granule lumenNeutrophil collagenaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil collagenaseHomo sapiens (human)
tertiary granule lumenNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
extracellular regionMacrophage metalloelastaseHomo sapiens (human)
extracellular spaceMacrophage metalloelastaseHomo sapiens (human)
nucleusMacrophage metalloelastaseHomo sapiens (human)
cytoplasmMacrophage metalloelastaseHomo sapiens (human)
extracellular matrixMacrophage metalloelastaseHomo sapiens (human)
extracellular spaceMacrophage metalloelastaseHomo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
cytoplasmMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
nucleusMatrix metalloproteinase-14Homo sapiens (human)
Golgi lumenMatrix metalloproteinase-14Homo sapiens (human)
cytosolMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
focal adhesionMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-14Homo sapiens (human)
cytoplasmic vesicleMatrix metalloproteinase-14Homo sapiens (human)
melanosomeMatrix metalloproteinase-14Homo sapiens (human)
macropinosomeMatrix metalloproteinase-14Homo sapiens (human)
intermediate filament cytoskeletonMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-15Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-15Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-15Homo sapiens (human)
Golgi lumenMatrix metalloproteinase-16Homo sapiens (human)
plasma membraneMatrix metalloproteinase-16Homo sapiens (human)
cell surfaceMatrix metalloproteinase-16Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-16Homo sapiens (human)
plasma membraneMatrix metalloproteinase-16Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-16Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
extracellular spaceDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
external side of plasma membraneDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
basolateral plasma membraneDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
extracellular exosomeDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
extracellular spaceDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-26Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-26Homo sapiens (human)
plasma membraneMatrix metalloproteinase-17Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-17Homo sapiens (human)
side of membraneMatrix metalloproteinase-17Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-17Homo sapiens (human)
extracellular regionA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular spaceA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
endoplasmic reticulum lumenA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
collagen-containing extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (178)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID409924Inhibition of human recombinant pro-MMP2 by spectrofluorimeter2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID1912269Inhibition of recombinant human MMP8 using MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1574105Inhibition of MT1-MMP-mediated proMMP-2 activation in human HT1080 cells stimulated with type I collagen for 24 hrs followed by compound addition at 0.1 to 10 uM and measured after 24 hrs by gelatin zymography assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).
AID359846Inhibition of MMP8 catalytic domain2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID1294563Selectivity ratio of IC50 for human recombinant MMP9 to IC50 for human recombinant MMP22016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID259464Inhibitory activity against MMP262006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID1200530Toxicity in C57BL6 mouse bleeding model assessed as thrombin formation in liver at 10 mg/kg after 24 hrs by anatomopathological analysis2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
AID1912255Inhibition of recombinant human MMP13 using MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID109571Inhibition of matrix metalloprotease-15 (MMP-15)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID109567Inhibition of matrix metalloprotease-14 (MMP-14)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID324581Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1294564AUC (0 to infinity) in Sprague-Dawley rat at 10 mg/kg, iv after 15 mins to 24 hrs by LC-MS/MS method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID259459Inhibitory activity against MMP92006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID736089Inhibition of human recombinant ADAMTS4 expressed in HEk293 cells using FAM-AEwLQGRPISIAK-TAMRA as substrate measured for 15 mins by fluorometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID107164Inhibition of human matrix metalloprotease-22003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
AID1294562Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID1912292Selectivity ratio of IC50 for recombinant human MMP14 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1683068Inhibition of human MMP-9 by fluorometric assay
AID108308Inhibition of matrix metalloprotease-9 (MMP-9)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID109580Activity against Matrix metalloprotease-2 (MMP-2).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID1912291Selectivity ratio of IC50 for recombinant human MMP9 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1574115Inhibition of MT1-MMP-mediated proMMP-2 activation in human HT1080 cells stimulated with type I collagen for 24 hrs followed by compound addition assessed as reduction in processed form of MT1-MMP (40 KDa) level at 1 to 10 uM and measured after 24 hrs by 2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).
AID408844Inhibition of MMP12 at 0.0025 uM2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library.
AID1350390Inhibition of recombinant human C-terminal DYKDDDDK tagged MMP12 expressed in mammalian expression system at 1 uM2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID1294560AUC (0 to 24 hrs) in Sprague-Dawley rat at 10 mg/kg, iv by LC-MS/MS method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID1863874Inhibition of MMP-1 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1912266Inhibition of recombinant human MMP1 using MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1350385Inhibition of MMP9 (unknown origin) at 1 uM2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID108007Activity against Matrix metalloprotease-9 (MMP-9).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1350384Inhibition of MMP1 (unknown origin) at 1 uM2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID1863876Inhibition of MMP-3 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID360146Protection against anthrax PA63-lethal toxin complex-induced cytotoxicity in human U251 cells at 20 uM at 400 ng/ml by MTT test2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.
AID1350387Inhibition of MMP14 (unknown origin) at 1 uM2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID324399Induction of light chain 3-GFP level in human H4 cells at 6.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID409929Selectivity ratio of IC50 for human recombinant pro-MMP1 to IC50 for human recombinant pro-MMP92008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID108183The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9)1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Matrix metalloproteinase inhibitors: a structure-activity study.
AID736075Inhibition of ADAMTS5 in pig articular cartilage assessed as inhibition of IL1alpha-induced aggrecan cleavage at 100 uM after 24 hrs by Western blot analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID359849Inhibition of MMP12 catalytic domain2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID1294561Inhibition of human recombinant MMP2 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID359847Inhibition of MMP92007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID107987The compound was tested for its binding affinity towards neutrophil collagenase (Matrix metalloprotease-8)1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Matrix metalloproteinase inhibitors: a structure-activity study.
AID1683069Inhibition of human MMP-3 by fluorometric assay
AID409923Inhibition of human recombinant pro-MMP1 by spectrofluorimeter2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID1594402Inhibition of cell migration of human A375M6 cells at 1 to 10 uM incubated for 6 hrs by Boyden chambers assay2019Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9
Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.
AID359843Inhibition of MMP22007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID1863875Inhibition of MMP-2 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID448178Inhibition of ADAM92009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID1574114Inhibition of MT1-MMP-mediated proMMP-2 activation in human HT1080 cells stimulated with type I collagen for 24 hrs followed by compound addition assessed as increase in active MT1-MMP (55 KDa) level at 1 to 10 uM and measured after 24 hrs by Western blot2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).
AID409925Inhibition of human recombinant pro-MMP9 by spectrofluorimeter2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID108737Inhibition of matrix metalloprotease-12003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.
AID1912257Selectivity ratio of IC50 for recombinant human MMP13 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID107324Binding affinity towards 72 kDa gelatinase (Matrix metalloprotease-2)1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Matrix metalloproteinase inhibitors: a structure-activity study.
AID736083Inhibition of human recombinant MMP14 catalytic domain using Mca-Lys-Pro- Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to substrate addition measured every 15 secs for 15 mins by fluorometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID259462Inhibitory activity against MMP152006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID299880Inhibition of MMP32007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
AID1912270Inhibition of recombinant human MMP9 using MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID628296Inhibition of MMP142011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1863882Inhibition of MMP-14 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID241656In vitro inhibition of A disintegrin and metalloprotease domain 9 (ADAM9)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID259461Inhibitory activity against MMP142006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID107348Inhibition of matrix metalloprotease-26 (MMP-26)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1699669Inhibition of recombinant human His-tagged MMP3 catalytic domain (Pro19 to Glu271 residues) expressed in Escherichia coli at 4 to 25 nM using 5-FAM/QXL520 FRET peptide as substrate preincubated for 15 mins followed by substrate addition and measured at 3 2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID259456Inhibitory activity against MMP12006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID359845Inhibition of MMP72007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID299879Inhibition of MMP22007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
AID324579Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID359848Inhibition of MMP14 catalytic domain2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID1912290Selectivity ratio of IC50 for recombinant human MMP8 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID109575Inhibition of matrix metalloprotease-16 (MMP-16)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID736085Inhibition of human recombinant MMP2 using Mca-Lys-Pro- Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to substrate addition measured every 15 secs for 15 mins by fluorometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID1912268Inhibition of recombinant human MMP7 using MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID107338Inhibition of matrix metalloprotease-2 (MMP-2)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1912267Inhibition of recombinant human MMP3 using MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-N2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID109082Inhibition of matrix metalloprotease-1 (MMP-1)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID736087Inhibition of human recombinant ADAMTS5 expressed in HEK293 cells using Abz-TESEwSRGAIY-Dpa-KK as substrate measured for 2 hrs by fluorometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1294566Terminal half life in Sprague-Dawley rat at 10 mg/kg, iv by LC-MS/MS method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID1574108Inhibition of MT1-MMP-mediated proMMP-2 activation in human HT1080 cells stimulated with type I collagen for 24 hrs followed by compound addition assessed as increase in proMT1-MMP (65 KDa) level at 1 to 10 uM and measured after 24 hrs by Western blot ana2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).
AID324503Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 6.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID408845Inhibition of MMP122008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID359841Inhibition of human recombinant MMP13 catalytic domain2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID359850Inhibition of MMP17 catalytic domain2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID628298Inhibition of MMP92011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1912288Selectivity ratio of IC50 for recombinant human MMP3 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1574119Inhibition of MT1-MMP mediated collagenolytic activity in human HT1080 cells stimulated with type I collagen for 48 hrs followed by compound addition at 10 uM and measured after 48 hrs by Coomassie Blue staining-based collagen film degradation assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).
AID324580Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1200531Toxicity in C57BL6 mouse bleeding model assessed as thrombin formation in lungs at 10 mg/kg after 24 hrs by anatomopathological analysis2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
AID208190The compound was tested for its binding affinity towards stromelysin.1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Matrix metalloproteinase inhibitors: a structure-activity study.
AID107358Activity against Matrix metalloprotease-3 (MMP-3).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID1912271Inhibition of recombinant human MMP14 using MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID324451Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 6.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID409927Inhibition of human recombinant MMP14 catalytic domain by spectrofluorimeter2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID1200529Toxicity in C57BL6 mouse bleeding model assessed as thrombin formation in brain at 10 mg/kg after 24 hrs by anatomopathological analysis2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
AID1350386Inhibition of recombinant human C-terminal DYKDDDDK tagged MMP13 expressed in mammalian expression system at 1 uM2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID299878Inhibition of MMP12007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
AID409933Selectivity ratio of IC50 for human recombinant MMP14 catalytic domain to IC50 for human recombinant pro-MMP92008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID1200527Antifibrinolytic activity in C57BL6 mouse bleeding model assessed as reduction in tPA-induced bleeding time at 1 mg/kg/hr measured up to 30 mins by spectrophotometry (Rvb = 29.28 +/- 0.4 mins)2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID241679In vitro inhibition of A disintegrin and metalloprotease domain 10 (ADAM10)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID107180Inhibition of Matrix metalloprotease-22001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID1294578Oral bioavailability in Sprague-Dawley rat at 10 mg/kg by LC-MS/MS method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1912289Selectivity ratio of IC50 for recombinant human MMP7 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID359844Inhibition of MMP3 catalytic domain2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID259460Inhibitory activity against MMP122006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID241883In vitro inhibition of A disintegrin and metalloprotease domain 17 (ADAM17, TACE)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID1294579Lipid-water partition coefficient, logP of compound2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID242091Inhibition of A disintegrin and metalloprotease domain 12 (ADAM12) binding in cell based assay2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID1863879Inhibition of MMP-9 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID109243Inhibition of matrix metalloprotease-12 (MMP-12)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID628299Inhibition of MMP32011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID409930Selectivity ratio of IC50 for human recombinant pro-MMP2 to IC50 for human recombinant pro-MMP92008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID107666Selectivity ratio for Matrix metalloprotease-2 over Matrix metalloprotease-3 (IC50)2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
AID299882Inhibition of MMP142007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
AID1912253Inhibition of recombinant human MMP2 using MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as a substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID107521Inhibition of Matrix metalloprotease-32001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID259463Inhibitory activity against MMP162006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID1863878Inhibition of MMP-8 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID736086Inhibition of human recombinant MMP1 using Mca-Lys-Pro- Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to substrate addition measured every 15 secs for 15 mins by fluorometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID409926Inhibition of human recombinant pro-MMP7 by spectrofluorimeter2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID736084Inhibition of human recombinant MMP13 using Mca-Lys-Pro- Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to substrate addition measured every 15 secs for 15 mins by fluorometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID1683070Inhibition of human MMP-2 by fluorometric assay
AID448179Inhibition of ADAM102009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID1574106Inhibition of MT1-MMP-mediated proMMP-2 activation in human HT1080 cells stimulated with type I collagen for 24 hrs followed by compound addition at 0.01 uM and measured after 24 hrs by gelatin zymography assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).
AID1912256Selectivity ratio of IC50 for recombinant human MMP12 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1200532Toxicity in C57BL6 mouse bleeding model assessed as thrombin formation in kidney at 10 mg/kg after 24 hrs by anatomopathological analysis2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
AID736078Inhibition of ADAMTS5 in pig articular cartilage assessed as inhibition of IL1alpha-induced glycosaminoglycan release at 100 uM after 24 hrs by DMMB method2013European journal of medicinal chemistry, Apr, Volume: 62Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.
AID628300Inhibition of MMP12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID409928Inhibition of human recombinant MMP3 catalytic domain by spectrofluorimeter2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID1294567Apparent clearance in Sprague-Dawley rat at 10 mg/kg, iv after 15 mins to 24 hrs by LC-MS/MS method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID107503Inhibition of human matrix metalloprotease-32003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
AID324555Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 6.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1350388Inhibition of recombinant human C-terminal DYKDDDDK tagged MMP3 expressed in mammalian expression system at 1 uM relative to control2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID1912254Inhibition of recombinant human MMP12 using MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition by fluroscence based assay2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1912287Selectivity ratio of IC50 for recombinant human MMP1 to IC50 for recombinant human MMP22022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
AID1294565Apparent volume of distribution in Sprague-Dawley rat at 10 mg/kg, iv after 15 mins to 24 hrs by LC-MS/MS method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
AID409931Selectivity ratio of IC50 for human recombinant MMP3 catalytic domain to IC50 for human recombinant pro-MMP92008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
AID220527Activity against deletion mutant of MT1-MMP lacking the transmembrane domain (deltaMT1)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID448180Inhibition of TACE2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID299881Inhibition of MMP92007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
AID107843Inhibition of matrix metalloprotease-7 (MMP-7) (No data)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1350382Inhibition of recombinant human MMP12 catalytic domain (Gly106 to Gly26 residues) expressed in Escherichia coli BL21 codon plus using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate by fluorescence assay2018ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
AID359842Inhibition of MMP12007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID259457Inhibitory activity against MMP22006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
AID108731Activity against Matrix metalloprotease-1 (MMP-1).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID1699663Inhibition of recombinant human MMP12 catalytic domain (Gly106 to Gly263 residues) expressed in Escherichia coli BL21 Codon Plus cells using 5-FAM/QXL520 FRET peptide as substrate preincubated for 15 mins followed by substrate addition and measured at 3 m2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.
AID107146Inhibition of Matrix metalloprotease-22003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345698Human MMP1 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345421Human ADAM12 (M12: Astacin/Adamalysin)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID1345455Human ADAM10 (M12: Astacin/Adamalysin)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID1345451Human MMP16 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345417Human MMP2 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345433Human ADAM9 (M12: Astacin/Adamalysin)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID1345458Human ADAM17 (M12: Astacin/Adamalysin)2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
AID1345412Human MMP12 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345442Human MMP9 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345456Human MMP17 (M10: Matrix metallopeptidase)2007The Journal of biological chemistry, Sep-21, Volume: 282, Issue:38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
AID1345448Human MMP15 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345454Human MMP26 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID1345436Human MMP14 (M10: Matrix metallopeptidase)2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2014Acta crystallographica. Section D, Biological crystallography, Nov, Volume: 70, Issue:Pt 11
Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.
AID1802980MMP-9 Assay from Article 10.3109/14756366.2010.487485: \\The evaluation of inhibitive effectiveness of the tumour necrosis factor-a converting enzyme selective inhibitors by HPLC.\\2011Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 26, Issue:2
The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC.
AID1802979TACE Assay from Article 10.3109/14756366.2010.487485: \\The evaluation of inhibitive effectiveness of the tumour necrosis factor-a converting enzyme selective inhibitors by HPLC.\\2011Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 26, Issue:2
The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (5.83)18.2507
2000's46 (44.66)29.6817
2010's39 (37.86)24.3611
2020's12 (11.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.76 (24.57)
Research Supply Index4.64 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.97%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other102 (99.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]